All In Biotech

Drug Trial Radar · NCT06142552

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Recombinant Human Coagulation Factor Ⅷ-Fc Fusion Protein (FRSW117) for Injection in Patients With Severe Hemophilia A (Adults and Adolescents)

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Dec 27, 2023

Primary completion

Oct 8, 2025

Study completion Oct 19, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the prophylactic efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A. To evaluate the safety of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A. Secondary purpose: To evaluate the efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein for injection (FRSW117) in hemostasis and surgical hemostasis in patients with severe hemophilia A. To evaluate the pharmacokinetic (PK) characteristics of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in treated patients with severe hemophilia A. To evaluate the immunogenicity of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in treated patients with severe hemophilia A.

Conditions

  • Severe Hemophilia A

Interventions

  • FRSW117Drug

    once a week, 50 weeks and as needed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ABRTime frame: 1year
  2. Effective rate of bleeding treatmentTime frame: 2year
  3. Safety evaluationTime frame: 3year
  4. Adverse events/reactionsTime frame: ALL
  5. Immunogenicity evaluationTime frame: ALL

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing tongren hospital,CMU

    Beijing, China

  • XiangYa Hospital CentralSouth University

    Changsha, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, China

  • The First Affiliated Hospital,Zhejiang University School of Medicine

    Hangzhou, China

  • Anhui Provincial Hospital

    Hefei, China

  • Jinan central hospital

    Jinan, China

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, China

  • The First Hospital of Lanzhou University

    Lanzhou, China

  • Jiangxi Provincial People's Hospital

    Nanchang, China

  • Nanjing Drum Tower Hospital

    Nanjing, China

  • Affiliated Hospital of Nantong University

    Nantong, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, China

  • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine

    Shanghai, China

  • Shenzhen Second People's Hospital

    Shenzhen, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, China

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, China

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, China

  • Affiliated Hospital of Jiangnan University

    Wuxi, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • Zhenyu Li

    Xuzhou, China

  • Subei People's Hospital of Jiangsu province

    Yangzhou, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Henan Provincial People's Hospital

    Zhengzhou, China

  • Zhengzhou People's Hospital

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.